The New England journal of medicine
-
Randomized Controlled Trial Comparative Study
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. ⋯ First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
-
Randomized Controlled Trial Multicenter Study
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019. ⋯ TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ClinicalTrials.gov number, NCT02747927.).
-
Editorial Comment
Fecal Microbiota Transplantation for Dysbiosis - Predictable Risks.